Eden Research (LON:EDEN) Shares Down 13.2% – What’s Next?

Eden Research plc (LON:EDEN) traded down 13.2% during mid-day trading on Tuesday . The company traded as low as GBX 2.26 ($0.03) and last traded at GBX 2.37 ($0.03). 1,775,147 shares were traded during mid-day trading, an increase of 133% from the average session volume of 762,776 shares. The stock had previously closed at GBX 2.73 ($0.04).

Eden Research Stock Performance

The firm’s fifty day moving average is GBX 3.34 and its 200 day moving average is GBX 3.70. The firm has a market capitalization of £13.87 million, a price-to-earnings ratio of -9.11 and a beta of 0.92. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.80 and a quick ratio of 2.42.

Insiders Place Their Bets

In other news, insider Alexander John Abrey purchased 167,947 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was acquired at an average price of GBX 3 ($0.04) per share, with a total value of £5,038.41 ($6,542.54). Also, insider Sean M. Smith acquired 426,986 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The shares were acquired at an average cost of GBX 234 ($3.04) per share, for a total transaction of £999,147.24 ($1,297,425.32). Insiders purchased a total of 1,391,473 shares of company stock worth $103,604,725 in the last quarter. 14.02% of the stock is currently owned by corporate insiders.

Eden Research Company Profile

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden’s products are formulated with terpene active ingredients, based on natural plant defence metabolites.